Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation

• US 20110052546A1
• Filed: 01/18/2010
• Published: 03/03/2011
• Est. Priority Date: 09/19/2000
• Status: Abandoned Application

• Current Assignee: University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Wahle, Joseph, Desponts, Caroline, Ninos, John M., Kerr, William G.
• Application Number:
  US12/689,167
• Publication Number:
  US 20110052546A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/53 partially self-complementary or closed

Abstract

The instant invention teaches the inhibition of SHIP expression, or function for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such as leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary).

Claims

1. A method of increasing the yield of stem cells from a patient, ex vivo, comprising:

harvesting target stem cells from the patient;

contacting the target stem cells with a SHIP inhibitor.

2. The method of claim 1, wherein the SHIP inhibitor is selected from the group consisting of RNA interference compounds, antisense oligonucleotides, ribozymes, DNAzymes, nucleic acid modifiers, PNAs, nonstandard nucleic acids, aptamers, decoys, oligonucleotide based gene regulation, substrate mimics, molecular inhibitors and dominant/negative mutants.

3. The method of claim 1, wherein the harvested target stem cells are selected from the group consisting of hematopoietic stem cells, mammary stem cells, mesenchymal stem cells, and organ specific stem cells.

4. The method of claim 1, wherein the SHIP inhibitor is an RNA interference compound.

5. The method of claim 1, wherein the target stem cells are transplanted into the patient after said harvesting and contacting.

6. The method of claim 1, wherein the target stem cells are allowed to propagate in the presence of the SHIP inhibitor to increase the number of stem cells.

7. The method of claim 6, wherein a therapeutically effective amount of the propagated cells is transplanted into the patient.

8. The method of claim 1, wherein the SHIP inhibitor is an RNA interference compound, and wherein the target stem cells are transplanted into the patient after said harvesting and contacting.

9. The method of claim 8, wherein the target stem cells are allowed to propagate in the presence of the SHIP inhibitor to increase the number of stem cells.

10. The method of claim 9, wherein a therapeutically effective amount of the propagated cells is transplanted into the patient.